Chiropractors in Ferndale, WA Accepting Medicare

12 Chiropractors found. Showing 1 - 12

Dr. Terry R. Rouse, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2116 Main Street, Ferndale, WA 98248 Phone: 360-312-8822    Fax: 360-312-8002

Dr. Christopher Muheim, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 2376 Main St Ste 1, Ferndale, WA 98248 Phone: 360-312-4656

Charles Jeffery, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1943 Main St., Ferndale, WA 98248 Phone: 360-384-1396    Fax: 360-384-1365

Genesis Chiropractic Center Inc Ps Chiropractor Medicare: Medicare Enrolled Practice Location: 5630 3rd St, Ferndale, WA 98248 Phone: 360-380-4848

Pierre R Constantin, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2376 Main Street, Suite 1, Ferndale, WA 98248 Phone: 360-312-4656    Fax: 360-392-8732

Dr. Susan M Constantin, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2017 Main St., Ferndale, WA 98248 Phone: 360-384-4611    Fax: 360-384-2574

Dr. Mark Alexander Mielke, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 5630 3rd St, Ferndale, WA 98248 Phone: 360-380-4848    Fax: 360-384-7416

Natural Way Chiropractic Of Ferndale Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1943 Main St., Ferndale, WA 98248 Phone: 360-384-1396    Fax: 360-384-1365

Rouse Chiropractic Clinic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2116 Main Street, Ferndale, WA 98248 Phone: 360-312-8822    Fax: 360-312-8002

Dr. Gregg Harlen Fusman, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5679 3rd St, Ferndale, WA 98248 Phone: 360-384-0918

Constantin Chiropractic Clinic Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 2017 Main St, Ferndale, WA 98248 Phone: 360-384-4611    Fax: 360-384-2574

Ferndale Chiropractic Clinic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 2376 Main St Ste 1, Ferndale, WA 98248 Phone: 360-312-4656    Fax: 360-392-8732

News Archive

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home and often have fewer side effects than older drugs, can cost patients thousands of dollars a month, while receiving chemotherapy through an IV in an infusion center typically amounts to a standard co-payment for an office visit.

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists at the University of California, San Diego School of Medicine have elucidated a genetic interaction that may prove key to the development and progression of glaucoma, a blinding neurodegenerative disease that affects tens of millions of people worldwide and is a leading cause of irreversible blindness.

Scientists at NIH and Emory University induce sustained remission in SIV-infected monkeys

Scientists at the National Institutes of Health and Emory University have experimentally induced sustained remission of SIV, the simian form of HIV, in infected monkeys.

AMT, NIH enter exclusive license agreement for use of AAV5-based gene therapy vectors

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.

Pfizer's 20vPnC vaccine receives Breakthrough Therapy designation from FDA

Pfizer Inc. announced today that its 20-Valent Pneumococcal Conjugate Vaccine candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. Pfizer expects to start Phase 3 trials in a few months.

Read more Medical News

› Verified 4 days ago